2022 ICD-10-CM Diagnosis Code E75.22

Gaucher disease

    2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
  • E75.22 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2022 edition of ICD-10-CM E75.22 became effective on October 1, 2021.
  • This is the American ICD-10-CM version of E75.22 - other international versions of ICD-10 E75.22 may differ.
The following code(s) above E75.22 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to E75.22:
  • E00-E89
    2022 ICD-10-CM Range E00-E89

    Endocrine, nutritional and metabolic diseases

    • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
    Type 1 Excludes
    • transitory endocrine and metabolic disorders specific to newborn (P70-P74)
    Endocrine, nutritional and metabolic diseases
  • E70-E88
    2022 ICD-10-CM Range E70-E88

    Metabolic disorders

    Type 1 Excludes
    • androgen insensitivity syndrome (E34.5-)
    • congenital adrenal hyperplasia (E25.0)
    • hemolytic anemias attributable to enzyme disorders (D55.-)
    • Marfan's syndrome (Q87.4)
    • 5-alpha-reductase deficiency (E29.1)
    Type 2 Excludes
    • Ehlers-Danlos syndromes (Q79.6-)
    Metabolic disorders
  • E75
    ICD-10-CM Diagnosis Code E75

    Disorders of sphingolipid metabolism and other lipid storage disorders

      2016 2017 2018 2019 2020 2021 2022 Non-Billable/Non-Specific Code
    Type 1 Excludes
    Disorders of sphingolipid metabolism and other lipid storage disorders
  • E75.2
    ICD-10-CM Diagnosis Code E75.2

    Other sphingolipidosis

      2016 2017 2018 2019 2020 2021 2022 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • adrenoleukodystrophy [Addison-Schilder] (E71.528)
    Other sphingolipidosis
Approximate Synonyms
  • Gaucher's disease
  • Gauchers disease
Clinical Information
  • An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (glucosylceramidase) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the mononuclear phagocyte system. The characteristic gaucher cells, glycosphingolipid-filled histiocytes, displace normal cells in bone marrow and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.
  • An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.
  • Autosomal recessive disorder caused by deficiency of the enzyme glucocerebrosidase featuring the pathological storage of glycosylceramide in mononuclear phagocytes; the most common subtype is the non-neuronopathic form, a slowly progressive condition characterized by hepatosplenomegaly and skeletal deformities; the neuronopathic forms are divided into infantile and juvenile forms; the infantile form presents at 4-5 months of age with anemia, loss of cognitive gains, neck retraction, dysphagia, and hepatosplenomegaly; the juvenile form features a slowly progressive loss of intellect, hepatosplenomegaly, ataxia, myoclonic seizures, and spasticity; the neuronopathic forms are characterized by neuronal loss with neuronophagia, and accumulation of glucocerebroside in neurons.
  • Gaucher's disease is a rare, inherited disorder that causes too much of a substance called glucocerebroside to build up in your spleen, liver, lungs, bones and sometimes in your brain. The buildup prevents these organs from working properly.there are three types:
    • type 1, the most common form, causes liver and spleen enlargement, bone pain and broken bones, and, sometimes, lung and kidney problems. It does not involve the brain. It can occur at any age.
    • type 2, which causes severe brain damage, appears in infants. Most children who have it die by age 2.
    • in type 3, there may be liver and spleen enlargement, and signs of brain involvement appear gradually.
    gaucher's disease has no cure. Treatment options for types 1 and 3 include medicine and enzyme replacement therapy, which is usually very effective. There is no good treatment for the brain damage of type 2.
ICD-10-CM E75.22 is grouped within Diagnostic Related Group(s) (MS-DRG v39.0):
  • 642 Inborn and other disorders of metabolism

Convert E75.22 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
Code annotations containing back-references to E75.22:
  • Code Also: I27.29
    ICD-10-CM Diagnosis Code I27.29

    Other secondary pulmonary hypertension

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    Applicable To
    • Group 5 pulmonary hypertension
    • Pulmonary hypertension with unclear multifactorial mechanisms
    • Pulmonary hypertension due to hematologic disorders
    • Pulmonary hypertension due to metabolic disorders
    • Pulmonary hypertension due to other systemic disorders
    Code Also
    • other associated disorders, if known, such as:
    • chronic myeloid leukemia (C92.10-C92.22)
    • essential thrombocythemia (D47.3)
    • Gaucher disease (E75.22)
    • hypertensive chronic kidney disease with end stage renal disease (I12.0, I13.11, I13.2)
    • hyperthyroidism (E05.-)
    • hypothyroidism (E00-E03)
    • polycythemia vera (D45)
    • sarcoidosis (D86.-)

Diagnosis Index entries containing back-references to E75.22:
  • Cerebroside lipidosis E75.22
  • Degeneration, degenerative
    • brain (cortical) (progressive) G31.9
      ICD-10-CM Diagnosis Code G31.9

      Degenerative disease of nervous system, unspecified

        2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
      • in
        • Gaucher's disease E75.22
  • Gaucher's disease or splenomegaly E75.22 (adult) (infantile)
  • Lipidosis E75.6
    ICD-10-CM Diagnosis Code E75.6

    Lipid storage disorder, unspecified

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    • cerebroside E75.22
  • Splenomegaly, splenomegalia (Bengal) (cryptogenic) (idiopathic) (tropical) R16.1
    ICD-10-CM Diagnosis Code R16.1

    Splenomegaly, not elsewhere classified

      2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code
    Applicable To
    • Splenomegaly NOS
    • Gaucher's E75.22

ICD-10-CM Codes Adjacent To E75.22
E75.00 …… unspecified
E75.01 Sandhoff disease
E75.02 Tay-Sachs disease
E75.09 Other GM2 gangliosidosis
E75.1 Other and unspecified gangliosidosis
E75.10 Unspecified gangliosidosis
E75.11 Mucolipidosis IV
E75.19 Other gangliosidosis
E75.2 Other sphingolipidosis
E75.21 Fabry (-Anderson) disease
E75.22 Gaucher disease
E75.23 Krabbe disease
E75.24 Niemann-Pick disease
E75.240 …… type A
E75.241 …… type B
E75.242 …… type C
E75.243 …… type D
E75.244 …… type A/B
E75.248 Other Niemann-Pick disease
E75.249 …… unspecified
E75.25 Metachromatic leukodystrophy

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.